Inclusion Criteria:

- Histologically confirmed Hodgkin's lymphoma or Non-Hodgkin's lymphoma receiving Q14,
Q21, or Q28 day CHOP, ICE, ESHAP, or DHAP chemotherapy; with or without Rituximab

- Has adequate bone marrow function; platelet count > 100 x 10^9/L on the day of
initiation of the on study chemotherapy of the next treatment cycle and absolute
neutrophil count, ANC > or = 1 x 10^9/L, and hemoglobin > or = 9.5 g/dL

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Has adequate liver function

- must be able to receive the same chemotherapy regimen during the first treatment
cycle as was received during the prior qualifying cycle

- must experience Common Terminology Criteria (CTC) grade 3 or 4 thrombocytopenia
(platelet count < 50 x 10^9/L) as a result of the chemotherapy administered in the
cycle immediately preceding study entry

- has serum creatinine concentration < or = 2 mg/dl

Exclusion Criteria:

- More that 1 prior relapse chemotherapy regimen

- Sepsis, disseminated coagulation or any other condition that may exacerbate
thrombocytopenia

- Significant bleeding (CTC grade 3 or 4)

- History of thromboembolic disease

- Subjects who are identified by clinical history and/or serological testing to have
either acute or chronic hepatitis B or C infection or to be HIV positive

- Use of any nitrosourea or mitomycin-C

- Has received any thrombocytopenic growth factor

- Has received a marrow or peripheral blood stem cell infusion

- Known hypersensitivity to any recombinant E. coli-derived product